nodes	percent_of_prediction	percent_of_DWPC	metapath
Tolterodine—CYP2C19—prostate cancer	0.181	0.611	CbGaD
Tolterodine—CYP3A4—prostate cancer	0.115	0.389	CbGaD
Tolterodine—CYP2C19—Nilutamide—prostate cancer	0.0355	0.0816	CbGbCtD
Tolterodine—CYP2C19—Bicalutamide—prostate cancer	0.0355	0.0816	CbGbCtD
Tolterodine—CYP3A4—Estradiol valerate/Dienogest—prostate cancer	0.0326	0.0751	CbGbCtD
Tolterodine—CYP2C9—Bicalutamide—prostate cancer	0.0295	0.0679	CbGbCtD
Tolterodine—CYP2C9—Nilutamide—prostate cancer	0.0295	0.0679	CbGbCtD
Tolterodine—CYP2C19—Flutamide—prostate cancer	0.0294	0.0676	CbGbCtD
Tolterodine—CYP2D6—Bicalutamide—prostate cancer	0.027	0.062	CbGbCtD
Tolterodine—CYP2D6—Abiraterone—prostate cancer	0.0223	0.0514	CbGbCtD
Tolterodine—CYP2C9—Estrone—prostate cancer	0.0177	0.0406	CbGbCtD
Tolterodine—CYP3A4—Bicalutamide—prostate cancer	0.0171	0.0395	CbGbCtD
Tolterodine—CYP3A4—Estramustine—prostate cancer	0.0159	0.0367	CbGbCtD
Tolterodine—CYP3A4—Flutamide—prostate cancer	0.0142	0.0327	CbGbCtD
Tolterodine—CYP3A4—Abiraterone—prostate cancer	0.0142	0.0327	CbGbCtD
Tolterodine—CYP2C9—Capecitabine—prostate cancer	0.0134	0.0308	CbGbCtD
Tolterodine—CYP2C19—Estradiol—prostate cancer	0.0122	0.0281	CbGbCtD
Tolterodine—CYP3A4—Cabazitaxel—prostate cancer	0.0105	0.0242	CbGbCtD
Tolterodine—CYP2C19—Prednisone—prostate cancer	0.0105	0.0241	CbGbCtD
Tolterodine—CYP3A4—Estrone—prostate cancer	0.0103	0.0236	CbGbCtD
Tolterodine—CYP2C9—Estradiol—prostate cancer	0.0101	0.0233	CbGbCtD
Tolterodine—CHRM3—ureter—prostate cancer	0.00984	0.3	CbGeAlD
Tolterodine—CYP3A4—Ethinyl Estradiol—prostate cancer	0.00915	0.0211	CbGbCtD
Tolterodine—CYP3A4—Conjugated Estrogens—prostate cancer	0.00672	0.0155	CbGbCtD
Tolterodine—CYP3A4—Mitoxantrone—prostate cancer	0.00611	0.0141	CbGbCtD
Tolterodine—CYP3A4—Estradiol—prostate cancer	0.0059	0.0136	CbGbCtD
Tolterodine—CYP3A4—Prednisone—prostate cancer	0.00507	0.0117	CbGbCtD
Tolterodine—CYP2D6—Doxorubicin—prostate cancer	0.00413	0.00951	CbGbCtD
Tolterodine—CYP3A4—Etoposide—prostate cancer	0.00385	0.00886	CbGbCtD
Tolterodine—CYP3A4—Docetaxel—prostate cancer	0.00352	0.00811	CbGbCtD
Tolterodine—CYP2C19—urine—prostate cancer	0.00297	0.0905	CbGeAlD
Tolterodine—CYP3A4—Doxorubicin—prostate cancer	0.00263	0.00605	CbGbCtD
Tolterodine—CYP2C9—urine—prostate cancer	0.0023	0.0702	CbGeAlD
Tolterodine—CYP3A4—urine—prostate cancer	0.00176	0.0535	CbGeAlD
Tolterodine—CYP2D6—urine—prostate cancer	0.00173	0.0526	CbGeAlD
Tolterodine—CHRM5—epithelium—prostate cancer	0.00151	0.0459	CbGeAlD
Tolterodine—CHRM2—prostate gland—prostate cancer	0.00141	0.0429	CbGeAlD
Tolterodine—CHRM1—prostate gland—prostate cancer	0.00128	0.0391	CbGeAlD
Tolterodine—CHRM4—testis—prostate cancer	0.00116	0.0352	CbGeAlD
Tolterodine—CHRM3—prostate gland—prostate cancer	0.00115	0.0349	CbGeAlD
Tolterodine—KCNH2—prostate gland—prostate cancer	0.00102	0.031	CbGeAlD
Tolterodine—KCNH2—seminal vesicle—prostate cancer	0.000861	0.0262	CbGeAlD
Tolterodine—CHRM3—renal system—prostate cancer	0.000782	0.0238	CbGeAlD
Tolterodine—CHRM3—urethra—prostate cancer	0.000768	0.0234	CbGeAlD
Tolterodine—KCNH2—renal system—prostate cancer	0.000694	0.0211	CbGeAlD
Tolterodine—KCNH2—urethra—prostate cancer	0.000681	0.0207	CbGeAlD
Tolterodine—KCNH2—bone marrow—prostate cancer	0.000524	0.016	CbGeAlD
Tolterodine—CHRM3—testis—prostate cancer	0.000506	0.0154	CbGeAlD
Tolterodine—KCNH2—testis—prostate cancer	0.000448	0.0137	CbGeAlD
Tolterodine—CYP3A4—renal system—prostate cancer	0.00043	0.0131	CbGeAlD
Tolterodine—CYP2D6—renal system—prostate cancer	0.000423	0.0129	CbGeAlD
Tolterodine—Disopyramide—SLC22A1—prostate cancer	0.000361	0.147	CrCbGaD
Tolterodine—KCNH2—lymph node—prostate cancer	0.000325	0.0099	CbGeAlD
Tolterodine—Fesoterodine—CYP3A4—prostate cancer	0.000282	0.115	CrCbGaD
Tolterodine—CYP2D6—testis—prostate cancer	0.000273	0.00833	CbGeAlD
Tolterodine—Chlorphenamine—SLC22A1—prostate cancer	0.000263	0.107	CrCbGaD
Tolterodine—Labetalol—ADRB2—prostate cancer	0.000256	0.104	CrCbGaD
Tolterodine—Chlorphenamine—CYP3A5—prostate cancer	0.000213	0.0864	CrCbGaD
Tolterodine—Asthenia—Ethinyl Estradiol—prostate cancer	0.000194	0.00138	CcSEcCtD
Tolterodine—Influenza like illness—Doxorubicin—prostate cancer	0.000193	0.00137	CcSEcCtD
Tolterodine—Fatigue—Goserelin—prostate cancer	0.000192	0.00136	CcSEcCtD
Tolterodine—Palpitations—Estradiol—prostate cancer	0.000191	0.00136	CcSEcCtD
Tolterodine—Pain—Goserelin—prostate cancer	0.00019	0.00135	CcSEcCtD
Tolterodine—Constipation—Goserelin—prostate cancer	0.00019	0.00135	CcSEcCtD
Tolterodine—Fatigue—Conjugated Estrogens—prostate cancer	0.00019	0.00135	CcSEcCtD
Tolterodine—Pain—Conjugated Estrogens—prostate cancer	0.000188	0.00134	CcSEcCtD
Tolterodine—Constipation—Conjugated Estrogens—prostate cancer	0.000188	0.00134	CcSEcCtD
Tolterodine—Abnormal vision—Epirubicin—prostate cancer	0.000187	0.00133	CcSEcCtD
Tolterodine—Bronchitis—Capecitabine—prostate cancer	0.000186	0.00132	CcSEcCtD
Tolterodine—Diarrhoea—Ethinyl Estradiol—prostate cancer	0.000185	0.00131	CcSEcCtD
Tolterodine—Chest pain—Estradiol—prostate cancer	0.000184	0.00131	CcSEcCtD
Tolterodine—Arthralgia—Estradiol—prostate cancer	0.000184	0.00131	CcSEcCtD
Tolterodine—Dry eye—Doxorubicin—prostate cancer	0.000183	0.0013	CcSEcCtD
Tolterodine—Anxiety—Estradiol—prostate cancer	0.000183	0.0013	CcSEcCtD
Tolterodine—Feeling abnormal—Goserelin—prostate cancer	0.000183	0.0013	CcSEcCtD
Tolterodine—Dry skin—Prednisone—prostate cancer	0.000182	0.0013	CcSEcCtD
Tolterodine—Gastrointestinal pain—Goserelin—prostate cancer	0.000182	0.00129	CcSEcCtD
Tolterodine—Weight increased—Docetaxel—prostate cancer	0.000182	0.00129	CcSEcCtD
Tolterodine—Dysuria—Capecitabine—prostate cancer	0.000181	0.00128	CcSEcCtD
Tolterodine—Gastrointestinal pain—Conjugated Estrogens—prostate cancer	0.00018	0.00128	CcSEcCtD
Tolterodine—Dry mouth—Estradiol—prostate cancer	0.00018	0.00128	CcSEcCtD
Tolterodine—Upper respiratory tract infection—Capecitabine—prostate cancer	0.00018	0.00128	CcSEcCtD
Tolterodine—Dizziness—Ethinyl Estradiol—prostate cancer	0.000179	0.00127	CcSEcCtD
Tolterodine—Flushing—Etoposide—prostate cancer	0.000178	0.00127	CcSEcCtD
Tolterodine—Confusional state—Estradiol—prostate cancer	0.000178	0.00126	CcSEcCtD
Tolterodine—Anaphylactic shock—Estradiol—prostate cancer	0.000176	0.00125	CcSEcCtD
Tolterodine—Oedema—Estradiol—prostate cancer	0.000176	0.00125	CcSEcCtD
Tolterodine—Weight increased—Capecitabine—prostate cancer	0.000176	0.00125	CcSEcCtD
Tolterodine—Abdominal pain—Goserelin—prostate cancer	0.000176	0.00125	CcSEcCtD
Tolterodine—Infection—Estradiol—prostate cancer	0.000175	0.00124	CcSEcCtD
Tolterodine—Abdominal pain—Conjugated Estrogens—prostate cancer	0.000174	0.00124	CcSEcCtD
Tolterodine—Abnormal vision—Doxorubicin—prostate cancer	0.000173	0.00123	CcSEcCtD
Tolterodine—Tachycardia—Estradiol—prostate cancer	0.000172	0.00122	CcSEcCtD
Tolterodine—Chest pain—Mitoxantrone—prostate cancer	0.000171	0.00122	CcSEcCtD
Tolterodine—Arthralgia—Mitoxantrone—prostate cancer	0.000171	0.00122	CcSEcCtD
Tolterodine—Anxiety—Mitoxantrone—prostate cancer	0.000171	0.00121	CcSEcCtD
Tolterodine—Headache—Ethinyl Estradiol—prostate cancer	0.000169	0.0012	CcSEcCtD
Tolterodine—Urinary tract infection—Capecitabine—prostate cancer	0.000167	0.00119	CcSEcCtD
Tolterodine—Confusional state—Mitoxantrone—prostate cancer	0.000165	0.00118	CcSEcCtD
Tolterodine—Oedema—Mitoxantrone—prostate cancer	0.000164	0.00117	CcSEcCtD
Tolterodine—Anaphylactic shock—Mitoxantrone—prostate cancer	0.000164	0.00117	CcSEcCtD
Tolterodine—Hypersensitivity—Goserelin—prostate cancer	0.000164	0.00116	CcSEcCtD
Tolterodine—Infection—Mitoxantrone—prostate cancer	0.000163	0.00116	CcSEcCtD
Tolterodine—Hypersensitivity—Conjugated Estrogens—prostate cancer	0.000162	0.00115	CcSEcCtD
Tolterodine—Anaphylactoid reaction—Epirubicin—prostate cancer	0.000161	0.00114	CcSEcCtD
Tolterodine—Musculoskeletal discomfort—Estradiol—prostate cancer	0.00016	0.00114	CcSEcCtD
Tolterodine—Tachycardia—Mitoxantrone—prostate cancer	0.00016	0.00114	CcSEcCtD
Tolterodine—Asthenia—Goserelin—prostate cancer	0.000159	0.00113	CcSEcCtD
Tolterodine—Asthenia—Conjugated Estrogens—prostate cancer	0.000158	0.00112	CcSEcCtD
Tolterodine—Oedema peripheral—Docetaxel—prostate cancer	0.000157	0.00112	CcSEcCtD
Tolterodine—Somnolence—Estradiol—prostate cancer	0.000157	0.00111	CcSEcCtD
Tolterodine—Weight increased—Prednisone—prostate cancer	0.000157	0.00111	CcSEcCtD
Tolterodine—Dyspepsia—Estradiol—prostate cancer	0.000155	0.0011	CcSEcCtD
Tolterodine—Visual impairment—Docetaxel—prostate cancer	0.000154	0.00109	CcSEcCtD
Tolterodine—Oedema peripheral—Capecitabine—prostate cancer	0.000152	0.00108	CcSEcCtD
Tolterodine—Diarrhoea—Goserelin—prostate cancer	0.000152	0.00108	CcSEcCtD
Tolterodine—Fatigue—Estradiol—prostate cancer	0.000152	0.00108	CcSEcCtD
Tolterodine—Pain—Estradiol—prostate cancer	0.000151	0.00107	CcSEcCtD
Tolterodine—Constipation—Estradiol—prostate cancer	0.000151	0.00107	CcSEcCtD
Tolterodine—Diarrhoea—Conjugated Estrogens—prostate cancer	0.000151	0.00107	CcSEcCtD
Tolterodine—Vertigo—Etoposide—prostate cancer	0.00015	0.00107	CcSEcCtD
Tolterodine—Musculoskeletal discomfort—Mitoxantrone—prostate cancer	0.00015	0.00106	CcSEcCtD
Tolterodine—Visual impairment—Capecitabine—prostate cancer	0.000149	0.00106	CcSEcCtD
Tolterodine—Anaphylactoid reaction—Doxorubicin—prostate cancer	0.000149	0.00106	CcSEcCtD
Tolterodine—Brompheniramine—CYP2E1—prostate cancer	0.000149	0.0605	CrCbGaD
Tolterodine—Flushing—Docetaxel—prostate cancer	0.000148	0.00105	CcSEcCtD
Tolterodine—Brompheniramine—CYP2C19—prostate cancer	0.000147	0.0599	CrCbGaD
Tolterodine—Dizziness—Goserelin—prostate cancer	0.000147	0.00104	CcSEcCtD
Tolterodine—Somnolence—Mitoxantrone—prostate cancer	0.000146	0.00104	CcSEcCtD
Tolterodine—Dizziness—Conjugated Estrogens—prostate cancer	0.000146	0.00103	CcSEcCtD
Tolterodine—Feeling abnormal—Estradiol—prostate cancer	0.000145	0.00103	CcSEcCtD
Tolterodine—Dyspepsia—Mitoxantrone—prostate cancer	0.000144	0.00103	CcSEcCtD
Tolterodine—Gastrointestinal pain—Estradiol—prostate cancer	0.000144	0.00102	CcSEcCtD
Tolterodine—Flushing—Capecitabine—prostate cancer	0.000143	0.00102	CcSEcCtD
Tolterodine—Dry skin—Epirubicin—prostate cancer	0.000143	0.00101	CcSEcCtD
Tolterodine—Chest pain—Etoposide—prostate cancer	0.000142	0.00101	CcSEcCtD
Tolterodine—Fatigue—Mitoxantrone—prostate cancer	0.000141	0.00101	CcSEcCtD
Tolterodine—Constipation—Mitoxantrone—prostate cancer	0.00014	0.000997	CcSEcCtD
Tolterodine—Pain—Mitoxantrone—prostate cancer	0.00014	0.000997	CcSEcCtD
Tolterodine—Abdominal pain—Estradiol—prostate cancer	0.000139	0.000989	CcSEcCtD
Tolterodine—Headache—Goserelin—prostate cancer	0.000139	0.000989	CcSEcCtD
Tolterodine—Headache—Conjugated Estrogens—prostate cancer	0.000138	0.00098	CcSEcCtD
Tolterodine—Confusional state—Etoposide—prostate cancer	0.000138	0.000978	CcSEcCtD
Tolterodine—Hallucination—Prednisone—prostate cancer	0.000137	0.000974	CcSEcCtD
Tolterodine—Anaphylactic shock—Etoposide—prostate cancer	0.000137	0.00097	CcSEcCtD
Tolterodine—Infection—Etoposide—prostate cancer	0.000136	0.000964	CcSEcCtD
Tolterodine—Feeling abnormal—Mitoxantrone—prostate cancer	0.000135	0.000961	CcSEcCtD
Tolterodine—Gastrointestinal pain—Mitoxantrone—prostate cancer	0.000134	0.000954	CcSEcCtD
Tolterodine—Tachycardia—Etoposide—prostate cancer	0.000133	0.000947	CcSEcCtD
Tolterodine—Flatulence—Capecitabine—prostate cancer	0.000133	0.000942	CcSEcCtD
Tolterodine—Dry skin—Doxorubicin—prostate cancer	0.000132	0.000938	CcSEcCtD
Tolterodine—Hypersensitivity—Estradiol—prostate cancer	0.00013	0.000922	CcSEcCtD
Tolterodine—Abdominal pain—Mitoxantrone—prostate cancer	0.00013	0.000922	CcSEcCtD
Tolterodine—Bronchitis—Epirubicin—prostate cancer	0.000129	0.00092	CcSEcCtD
Tolterodine—Flushing—Prednisone—prostate cancer	0.000128	0.000908	CcSEcCtD
Tolterodine—Asthenia—Estradiol—prostate cancer	0.000126	0.000898	CcSEcCtD
Tolterodine—Disopyramide—CYP3A4—prostate cancer	0.000126	0.0513	CrCbGaD
Tolterodine—Dysuria—Epirubicin—prostate cancer	0.000126	0.000894	CcSEcCtD
Tolterodine—Upper respiratory tract infection—Epirubicin—prostate cancer	0.000125	0.000889	CcSEcCtD
Tolterodine—Phenprocoumon—CYP3A4—prostate cancer	0.000124	0.0503	CrCbGaD
Tolterodine—Palpitations—Docetaxel—prostate cancer	0.000123	0.000873	CcSEcCtD
Tolterodine—Weight increased—Epirubicin—prostate cancer	0.000122	0.00087	CcSEcCtD
Tolterodine—Atomoxetine—CYP2C19—prostate cancer	0.000122	0.0494	CrCbGaD
Tolterodine—Somnolence—Etoposide—prostate cancer	0.000121	0.000862	CcSEcCtD
Tolterodine—Vertigo—Capecitabine—prostate cancer	0.000121	0.000859	CcSEcCtD
Tolterodine—Hypersensitivity—Mitoxantrone—prostate cancer	0.000121	0.000859	CcSEcCtD
Tolterodine—Diarrhoea—Estradiol—prostate cancer	0.000121	0.000856	CcSEcCtD
Tolterodine—Bronchitis—Doxorubicin—prostate cancer	0.00012	0.000851	CcSEcCtD
Tolterodine—Palpitations—Capecitabine—prostate cancer	0.000119	0.000845	CcSEcCtD
Tolterodine—Chest pain—Docetaxel—prostate cancer	0.000118	0.000841	CcSEcCtD
Tolterodine—Arthralgia—Docetaxel—prostate cancer	0.000118	0.000841	CcSEcCtD
Tolterodine—Asthenia—Mitoxantrone—prostate cancer	0.000118	0.000837	CcSEcCtD
Tolterodine—Fatigue—Etoposide—prostate cancer	0.000118	0.000836	CcSEcCtD
Tolterodine—Constipation—Etoposide—prostate cancer	0.000117	0.00083	CcSEcCtD
Tolterodine—Pain—Etoposide—prostate cancer	0.000117	0.00083	CcSEcCtD
Tolterodine—Urinary tract infection—Epirubicin—prostate cancer	0.000117	0.000829	CcSEcCtD
Tolterodine—Dizziness—Estradiol—prostate cancer	0.000116	0.000828	CcSEcCtD
Tolterodine—Dysuria—Doxorubicin—prostate cancer	0.000116	0.000827	CcSEcCtD
Tolterodine—Dry mouth—Docetaxel—prostate cancer	0.000116	0.000822	CcSEcCtD
Tolterodine—Upper respiratory tract infection—Doxorubicin—prostate cancer	0.000116	0.000822	CcSEcCtD
Tolterodine—Chest pain—Capecitabine—prostate cancer	0.000115	0.000814	CcSEcCtD
Tolterodine—Arthralgia—Capecitabine—prostate cancer	0.000115	0.000814	CcSEcCtD
Tolterodine—Confusional state—Docetaxel—prostate cancer	0.000114	0.000813	CcSEcCtD
Tolterodine—Anxiety—Capecitabine—prostate cancer	0.000114	0.000811	CcSEcCtD
Tolterodine—Anaphylactic shock—Docetaxel—prostate cancer	0.000113	0.000806	CcSEcCtD
Tolterodine—Oedema—Docetaxel—prostate cancer	0.000113	0.000806	CcSEcCtD
Tolterodine—Weight increased—Doxorubicin—prostate cancer	0.000113	0.000805	CcSEcCtD
Tolterodine—Infection—Docetaxel—prostate cancer	0.000113	0.000801	CcSEcCtD
Tolterodine—Sinusitis—Epirubicin—prostate cancer	0.000113	0.0008	CcSEcCtD
Tolterodine—Feeling abnormal—Etoposide—prostate cancer	0.000112	0.000799	CcSEcCtD
Tolterodine—Diarrhoea—Mitoxantrone—prostate cancer	0.000112	0.000798	CcSEcCtD
Tolterodine—Dry mouth—Capecitabine—prostate cancer	0.000112	0.000796	CcSEcCtD
Tolterodine—Gastrointestinal pain—Etoposide—prostate cancer	0.000112	0.000793	CcSEcCtD
Tolterodine—Confusional state—Capecitabine—prostate cancer	0.000111	0.000787	CcSEcCtD
Tolterodine—Tachycardia—Docetaxel—prostate cancer	0.000111	0.000787	CcSEcCtD
Tolterodine—Headache—Estradiol—prostate cancer	0.00011	0.000784	CcSEcCtD
Tolterodine—Oedema—Capecitabine—prostate cancer	0.00011	0.000781	CcSEcCtD
Tolterodine—Angioedema—Prednisone—prostate cancer	0.00011	0.000778	CcSEcCtD
Tolterodine—Infection—Capecitabine—prostate cancer	0.000109	0.000775	CcSEcCtD
Tolterodine—Abdominal pain—Etoposide—prostate cancer	0.000108	0.000767	CcSEcCtD
Tolterodine—Urinary tract infection—Doxorubicin—prostate cancer	0.000108	0.000767	CcSEcCtD
Tolterodine—Vertigo—Prednisone—prostate cancer	0.000108	0.000765	CcSEcCtD
Tolterodine—Tachycardia—Capecitabine—prostate cancer	0.000107	0.000762	CcSEcCtD
Tolterodine—Oedema peripheral—Epirubicin—prostate cancer	0.000106	0.000754	CcSEcCtD
Tolterodine—Sinusitis—Doxorubicin—prostate cancer	0.000104	0.00074	CcSEcCtD
Tolterodine—Visual impairment—Epirubicin—prostate cancer	0.000104	0.000738	CcSEcCtD
Tolterodine—Musculoskeletal discomfort—Docetaxel—prostate cancer	0.000103	0.000734	CcSEcCtD
Tolterodine—Headache—Mitoxantrone—prostate cancer	0.000103	0.000731	CcSEcCtD
Tolterodine—Arthralgia—Prednisone—prostate cancer	0.000102	0.000725	CcSEcCtD
Tolterodine—Anxiety—Prednisone—prostate cancer	0.000102	0.000723	CcSEcCtD
Tolterodine—Somnolence—Docetaxel—prostate cancer	0.000101	0.000717	CcSEcCtD
Tolterodine—Hypersensitivity—Etoposide—prostate cancer	0.000101	0.000715	CcSEcCtD
Tolterodine—Musculoskeletal discomfort—Capecitabine—prostate cancer	0.0001	0.000711	CcSEcCtD
Tolterodine—Flushing—Epirubicin—prostate cancer	0.0001	0.00071	CcSEcCtD
Tolterodine—Dyspepsia—Docetaxel—prostate cancer	9.99e-05	0.00071	CcSEcCtD
Tolterodine—Oedema peripheral—Doxorubicin—prostate cancer	9.82e-05	0.000698	CcSEcCtD
Tolterodine—Asthenia—Etoposide—prostate cancer	9.79e-05	0.000696	CcSEcCtD
Tolterodine—Anaphylactic shock—Prednisone—prostate cancer	9.78e-05	0.000695	CcSEcCtD
Tolterodine—Oedema—Prednisone—prostate cancer	9.78e-05	0.000695	CcSEcCtD
Tolterodine—Fatigue—Docetaxel—prostate cancer	9.78e-05	0.000695	CcSEcCtD
Tolterodine—Infection—Prednisone—prostate cancer	9.72e-05	0.000691	CcSEcCtD
Tolterodine—Constipation—Docetaxel—prostate cancer	9.7e-05	0.000689	CcSEcCtD
Tolterodine—Pain—Docetaxel—prostate cancer	9.7e-05	0.000689	CcSEcCtD
Tolterodine—Dyspepsia—Capecitabine—prostate cancer	9.67e-05	0.000687	CcSEcCtD
Tolterodine—Visual impairment—Doxorubicin—prostate cancer	9.6e-05	0.000682	CcSEcCtD
Tolterodine—Tachycardia—Prednisone—prostate cancer	9.55e-05	0.000679	CcSEcCtD
Tolterodine—Fatigue—Capecitabine—prostate cancer	9.47e-05	0.000673	CcSEcCtD
Tolterodine—Constipation—Capecitabine—prostate cancer	9.39e-05	0.000667	CcSEcCtD
Tolterodine—Pain—Capecitabine—prostate cancer	9.39e-05	0.000667	CcSEcCtD
Tolterodine—Orphenadrine—CYP2E1—prostate cancer	9.37e-05	0.0381	CrCbGaD
Tolterodine—Brompheniramine—CYP3A4—prostate cancer	9.37e-05	0.0381	CrCbGaD
Tolterodine—Feeling abnormal—Docetaxel—prostate cancer	9.35e-05	0.000664	CcSEcCtD
Tolterodine—Diarrhoea—Etoposide—prostate cancer	9.34e-05	0.000664	CcSEcCtD
Tolterodine—Gastrointestinal pain—Docetaxel—prostate cancer	9.28e-05	0.000659	CcSEcCtD
Tolterodine—Flushing—Doxorubicin—prostate cancer	9.25e-05	0.000657	CcSEcCtD
Tolterodine—Flatulence—Epirubicin—prostate cancer	9.24e-05	0.000657	CcSEcCtD
Tolterodine—Chlorphenamine—CYP3A4—prostate cancer	9.2e-05	0.0374	CrCbGaD
Tolterodine—Feeling abnormal—Capecitabine—prostate cancer	9.05e-05	0.000643	CcSEcCtD
Tolterodine—Dizziness—Etoposide—prostate cancer	9.03e-05	0.000641	CcSEcCtD
Tolterodine—Gastrointestinal pain—Capecitabine—prostate cancer	8.98e-05	0.000638	CcSEcCtD
Tolterodine—Abdominal pain—Docetaxel—prostate cancer	8.97e-05	0.000637	CcSEcCtD
Tolterodine—Musculoskeletal discomfort—Prednisone—prostate cancer	8.91e-05	0.000633	CcSEcCtD
Tolterodine—Abdominal pain—Capecitabine—prostate cancer	8.68e-05	0.000617	CcSEcCtD
Tolterodine—Dyspepsia—Prednisone—prostate cancer	8.61e-05	0.000612	CcSEcCtD
Tolterodine—Headache—Etoposide—prostate cancer	8.55e-05	0.000608	CcSEcCtD
Tolterodine—Flatulence—Doxorubicin—prostate cancer	8.55e-05	0.000607	CcSEcCtD
Tolterodine—Fatigue—Prednisone—prostate cancer	8.44e-05	0.000599	CcSEcCtD
Tolterodine—Vertigo—Epirubicin—prostate cancer	8.42e-05	0.000599	CcSEcCtD
Tolterodine—Constipation—Prednisone—prostate cancer	8.37e-05	0.000595	CcSEcCtD
Tolterodine—Hypersensitivity—Docetaxel—prostate cancer	8.36e-05	0.000594	CcSEcCtD
Tolterodine—Palpitations—Epirubicin—prostate cancer	8.29e-05	0.000589	CcSEcCtD
Tolterodine—Asthenia—Docetaxel—prostate cancer	8.14e-05	0.000578	CcSEcCtD
Tolterodine—Hypersensitivity—Capecitabine—prostate cancer	8.09e-05	0.000575	CcSEcCtD
Tolterodine—Feeling abnormal—Prednisone—prostate cancer	8.06e-05	0.000573	CcSEcCtD
Tolterodine—Gastrointestinal pain—Prednisone—prostate cancer	8e-05	0.000569	CcSEcCtD
Tolterodine—Chest pain—Epirubicin—prostate cancer	7.98e-05	0.000567	CcSEcCtD
Tolterodine—Arthralgia—Epirubicin—prostate cancer	7.98e-05	0.000567	CcSEcCtD
Tolterodine—Anxiety—Epirubicin—prostate cancer	7.95e-05	0.000565	CcSEcCtD
Tolterodine—Asthenia—Capecitabine—prostate cancer	7.88e-05	0.00056	CcSEcCtD
Tolterodine—Dry mouth—Epirubicin—prostate cancer	7.81e-05	0.000555	CcSEcCtD
Tolterodine—Vertigo—Doxorubicin—prostate cancer	7.79e-05	0.000554	CcSEcCtD
Tolterodine—Diarrhoea—Docetaxel—prostate cancer	7.76e-05	0.000552	CcSEcCtD
Tolterodine—Abdominal pain—Prednisone—prostate cancer	7.73e-05	0.00055	CcSEcCtD
Tolterodine—Atomoxetine—CYP3A4—prostate cancer	7.73e-05	0.0314	CrCbGaD
Tolterodine—Confusional state—Epirubicin—prostate cancer	7.72e-05	0.000548	CcSEcCtD
Tolterodine—Palpitations—Doxorubicin—prostate cancer	7.67e-05	0.000545	CcSEcCtD
Tolterodine—Anaphylactic shock—Epirubicin—prostate cancer	7.65e-05	0.000544	CcSEcCtD
Tolterodine—Oedema—Epirubicin—prostate cancer	7.65e-05	0.000544	CcSEcCtD
Tolterodine—Infection—Epirubicin—prostate cancer	7.6e-05	0.00054	CcSEcCtD
Tolterodine—Diarrhoea—Capecitabine—prostate cancer	7.52e-05	0.000534	CcSEcCtD
Tolterodine—Dizziness—Docetaxel—prostate cancer	7.5e-05	0.000533	CcSEcCtD
Tolterodine—Tachycardia—Epirubicin—prostate cancer	7.47e-05	0.000531	CcSEcCtD
Tolterodine—Arthralgia—Doxorubicin—prostate cancer	7.39e-05	0.000525	CcSEcCtD
Tolterodine—Chest pain—Doxorubicin—prostate cancer	7.39e-05	0.000525	CcSEcCtD
Tolterodine—Anxiety—Doxorubicin—prostate cancer	7.36e-05	0.000523	CcSEcCtD
Tolterodine—Dizziness—Capecitabine—prostate cancer	7.26e-05	0.000516	CcSEcCtD
Tolterodine—Dry mouth—Doxorubicin—prostate cancer	7.22e-05	0.000513	CcSEcCtD
Tolterodine—Hypersensitivity—Prednisone—prostate cancer	7.21e-05	0.000512	CcSEcCtD
Tolterodine—Confusional state—Doxorubicin—prostate cancer	7.14e-05	0.000507	CcSEcCtD
Tolterodine—Headache—Docetaxel—prostate cancer	7.11e-05	0.000505	CcSEcCtD
Tolterodine—Anaphylactic shock—Doxorubicin—prostate cancer	7.08e-05	0.000503	CcSEcCtD
Tolterodine—Oedema—Doxorubicin—prostate cancer	7.08e-05	0.000503	CcSEcCtD
Tolterodine—Infection—Doxorubicin—prostate cancer	7.03e-05	0.0005	CcSEcCtD
Tolterodine—Asthenia—Prednisone—prostate cancer	7.02e-05	0.000499	CcSEcCtD
Tolterodine—Musculoskeletal discomfort—Epirubicin—prostate cancer	6.97e-05	0.000495	CcSEcCtD
Tolterodine—Tachycardia—Doxorubicin—prostate cancer	6.91e-05	0.000491	CcSEcCtD
Tolterodine—Headache—Capecitabine—prostate cancer	6.88e-05	0.000489	CcSEcCtD
Tolterodine—Somnolence—Epirubicin—prostate cancer	6.8e-05	0.000483	CcSEcCtD
Tolterodine—Dyspepsia—Epirubicin—prostate cancer	6.74e-05	0.000479	CcSEcCtD
Tolterodine—Diarrhoea—Prednisone—prostate cancer	6.69e-05	0.000476	CcSEcCtD
Tolterodine—Fatigue—Epirubicin—prostate cancer	6.6e-05	0.000469	CcSEcCtD
Tolterodine—Pain—Epirubicin—prostate cancer	6.54e-05	0.000465	CcSEcCtD
Tolterodine—Constipation—Epirubicin—prostate cancer	6.54e-05	0.000465	CcSEcCtD
Tolterodine—Dizziness—Prednisone—prostate cancer	6.47e-05	0.00046	CcSEcCtD
Tolterodine—Musculoskeletal discomfort—Doxorubicin—prostate cancer	6.45e-05	0.000458	CcSEcCtD
Tolterodine—Feeling abnormal—Epirubicin—prostate cancer	6.31e-05	0.000448	CcSEcCtD
Tolterodine—Somnolence—Doxorubicin—prostate cancer	6.29e-05	0.000447	CcSEcCtD
Tolterodine—Gastrointestinal pain—Epirubicin—prostate cancer	6.26e-05	0.000445	CcSEcCtD
Tolterodine—Dyspepsia—Doxorubicin—prostate cancer	6.23e-05	0.000443	CcSEcCtD
Tolterodine—Headache—Prednisone—prostate cancer	6.13e-05	0.000436	CcSEcCtD
Tolterodine—Fatigue—Doxorubicin—prostate cancer	6.1e-05	0.000434	CcSEcCtD
Tolterodine—Constipation—Doxorubicin—prostate cancer	6.05e-05	0.00043	CcSEcCtD
Tolterodine—Pain—Doxorubicin—prostate cancer	6.05e-05	0.00043	CcSEcCtD
Tolterodine—Abdominal pain—Epirubicin—prostate cancer	6.05e-05	0.00043	CcSEcCtD
Tolterodine—Orphenadrine—CYP3A4—prostate cancer	5.9e-05	0.024	CrCbGaD
Tolterodine—Feeling abnormal—Doxorubicin—prostate cancer	5.83e-05	0.000415	CcSEcCtD
Tolterodine—Gastrointestinal pain—Doxorubicin—prostate cancer	5.79e-05	0.000411	CcSEcCtD
Tolterodine—Hypersensitivity—Epirubicin—prostate cancer	5.64e-05	0.000401	CcSEcCtD
Tolterodine—Abdominal pain—Doxorubicin—prostate cancer	5.6e-05	0.000398	CcSEcCtD
Tolterodine—Asthenia—Epirubicin—prostate cancer	5.49e-05	0.00039	CcSEcCtD
Tolterodine—Diarrhoea—Epirubicin—prostate cancer	5.24e-05	0.000372	CcSEcCtD
Tolterodine—Hypersensitivity—Doxorubicin—prostate cancer	5.22e-05	0.000371	CcSEcCtD
Tolterodine—Asthenia—Doxorubicin—prostate cancer	5.08e-05	0.000361	CcSEcCtD
Tolterodine—Dizziness—Epirubicin—prostate cancer	5.06e-05	0.00036	CcSEcCtD
Tolterodine—Diarrhoea—Doxorubicin—prostate cancer	4.84e-05	0.000344	CcSEcCtD
Tolterodine—Headache—Epirubicin—prostate cancer	4.79e-05	0.000341	CcSEcCtD
Tolterodine—Dizziness—Doxorubicin—prostate cancer	4.68e-05	0.000333	CcSEcCtD
Tolterodine—Headache—Doxorubicin—prostate cancer	4.44e-05	0.000315	CcSEcCtD
Tolterodine—CHRM5—Signaling Pathways—CCND1—prostate cancer	3.15e-06	3.38e-05	CbGpPWpGaD
Tolterodine—CYP3A4—Metabolism—CYP2A6—prostate cancer	3.15e-06	3.37e-05	CbGpPWpGaD
Tolterodine—CYP2D6—Metabolism—TYMS—prostate cancer	3.14e-06	3.36e-05	CbGpPWpGaD
Tolterodine—CHRM5—Signaling Pathways—CTNNB1—prostate cancer	3.12e-06	3.34e-05	CbGpPWpGaD
Tolterodine—CYP2C9—Metabolism—TYMS—prostate cancer	3.12e-06	3.34e-05	CbGpPWpGaD
Tolterodine—CYP2D6—Metabolism—GSTM1—prostate cancer	3.11e-06	3.33e-05	CbGpPWpGaD
Tolterodine—CHRM1—Signaling Pathways—GSK3B—prostate cancer	3.11e-06	3.32e-05	CbGpPWpGaD
Tolterodine—CHRM4—Signaling by GPCR—AKT1—prostate cancer	3.1e-06	3.32e-05	CbGpPWpGaD
Tolterodine—CHRM3—Signaling Pathways—GSK3B—prostate cancer	3.1e-06	3.31e-05	CbGpPWpGaD
Tolterodine—CYP2C9—Metabolism—GSTM1—prostate cancer	3.08e-06	3.3e-05	CbGpPWpGaD
Tolterodine—CYP3A4—Metabolism—AKR1C3—prostate cancer	3.07e-06	3.28e-05	CbGpPWpGaD
Tolterodine—CHRM2—Signaling Pathways—GSK3B—prostate cancer	3.07e-06	3.28e-05	CbGpPWpGaD
Tolterodine—CHRM1—Signaling Pathways—INS—prostate cancer	3.06e-06	3.28e-05	CbGpPWpGaD
Tolterodine—CHRM5—Signaling Pathways—MMP9—prostate cancer	3.06e-06	3.28e-05	CbGpPWpGaD
Tolterodine—CHRM3—Signaling Pathways—INS—prostate cancer	3.05e-06	3.27e-05	CbGpPWpGaD
Tolterodine—CHRM5—Signaling Pathways—CDKN1A—prostate cancer	3.05e-06	3.27e-05	CbGpPWpGaD
Tolterodine—CYP3A4—Metabolism—PRKACB—prostate cancer	3.05e-06	3.27e-05	CbGpPWpGaD
Tolterodine—CYP2D6—Metabolism—LPL—prostate cancer	3.05e-06	3.26e-05	CbGpPWpGaD
Tolterodine—CHRM5—Signaling Pathways—PTEN—prostate cancer	3.04e-06	3.26e-05	CbGpPWpGaD
Tolterodine—CHRM4—Signaling Pathways—EP300—prostate cancer	3.03e-06	3.24e-05	CbGpPWpGaD
Tolterodine—CHRM2—Signaling Pathways—INS—prostate cancer	3.02e-06	3.24e-05	CbGpPWpGaD
Tolterodine—CYP2C9—Metabolism—LPL—prostate cancer	3.02e-06	3.24e-05	CbGpPWpGaD
Tolterodine—CYP3A4—Metabolism—CYP17A1—prostate cancer	3.02e-06	3.23e-05	CbGpPWpGaD
Tolterodine—CHRM1—Signaling Pathways—CREBBP—prostate cancer	3e-06	3.21e-05	CbGpPWpGaD
Tolterodine—CHRM3—Signaling Pathways—CREBBP—prostate cancer	2.99e-06	3.2e-05	CbGpPWpGaD
Tolterodine—CYP2C19—Metabolism—MTHFR—prostate cancer	2.99e-06	3.2e-05	CbGpPWpGaD
Tolterodine—CHRM5—Signaling by GPCR—AKT1—prostate cancer	2.97e-06	3.18e-05	CbGpPWpGaD
Tolterodine—CHRM1—Signaling Pathways—IGF1—prostate cancer	2.96e-06	3.17e-05	CbGpPWpGaD
Tolterodine—CHRM2—Signaling Pathways—CREBBP—prostate cancer	2.96e-06	3.17e-05	CbGpPWpGaD
Tolterodine—CHRM3—Metabolism—PIK3CB—prostate cancer	2.96e-06	3.16e-05	CbGpPWpGaD
Tolterodine—CHRM3—Signaling Pathways—IGF1—prostate cancer	2.95e-06	3.16e-05	CbGpPWpGaD
Tolterodine—CHRM1—Signaling by GPCR—EGFR—prostate cancer	2.95e-06	3.16e-05	CbGpPWpGaD
Tolterodine—CHRM4—Signaling Pathways—SRC—prostate cancer	2.95e-06	3.16e-05	CbGpPWpGaD
Tolterodine—CYP2D6—Metabolism—CYP1A1—prostate cancer	2.95e-06	3.15e-05	CbGpPWpGaD
Tolterodine—CHRM3—Signaling by GPCR—EGFR—prostate cancer	2.94e-06	3.15e-05	CbGpPWpGaD
Tolterodine—CHRM3—Metabolism—PTGS2—prostate cancer	2.93e-06	3.14e-05	CbGpPWpGaD
Tolterodine—CYP2C19—Metabolism—PPARA—prostate cancer	2.93e-06	3.14e-05	CbGpPWpGaD
Tolterodine—CHRM2—Signaling Pathways—IGF1—prostate cancer	2.93e-06	3.13e-05	CbGpPWpGaD
Tolterodine—CYP2D6—Metabolism—ERCC2—prostate cancer	2.92e-06	3.13e-05	CbGpPWpGaD
Tolterodine—CYP2C9—Metabolism—CYP1A1—prostate cancer	2.92e-06	3.13e-05	CbGpPWpGaD
Tolterodine—CHRM2—Signaling by GPCR—EGFR—prostate cancer	2.91e-06	3.12e-05	CbGpPWpGaD
Tolterodine—CHRM5—Signaling Pathways—EP300—prostate cancer	2.9e-06	3.11e-05	CbGpPWpGaD
Tolterodine—CYP2C9—Metabolism—ERCC2—prostate cancer	2.9e-06	3.1e-05	CbGpPWpGaD
Tolterodine—CYP3A4—Metabolism—NCOA2—prostate cancer	2.88e-06	3.08e-05	CbGpPWpGaD
Tolterodine—CHRM4—Signaling Pathways—VEGFA—prostate cancer	2.87e-06	3.07e-05	CbGpPWpGaD
Tolterodine—CHRM1—Signaling Pathways—MAP2K1—prostate cancer	2.86e-06	3.07e-05	CbGpPWpGaD
Tolterodine—CHRM3—Signaling Pathways—MAP2K1—prostate cancer	2.85e-06	3.06e-05	CbGpPWpGaD
Tolterodine—CHRM1—Signaling Pathways—PIK3CD—prostate cancer	2.85e-06	3.05e-05	CbGpPWpGaD
Tolterodine—CHRM4—Signaling Pathways—STAT3—prostate cancer	2.84e-06	3.04e-05	CbGpPWpGaD
Tolterodine—CHRM3—Signaling Pathways—PIK3CD—prostate cancer	2.84e-06	3.04e-05	CbGpPWpGaD
Tolterodine—CHRM2—Signaling Pathways—MAP2K1—prostate cancer	2.83e-06	3.03e-05	CbGpPWpGaD
Tolterodine—CHRM5—Signaling Pathways—SRC—prostate cancer	2.82e-06	3.02e-05	CbGpPWpGaD
Tolterodine—CHRM1—GPCR downstream signaling—PIK3CA—prostate cancer	2.82e-06	3.02e-05	CbGpPWpGaD
Tolterodine—CHRM1—Signaling Pathways—SERPINE1—prostate cancer	2.81e-06	3.01e-05	CbGpPWpGaD
Tolterodine—CHRM3—GPCR downstream signaling—PIK3CA—prostate cancer	2.81e-06	3.01e-05	CbGpPWpGaD
Tolterodine—CHRM2—Signaling Pathways—PIK3CD—prostate cancer	2.81e-06	3.01e-05	CbGpPWpGaD
Tolterodine—CHRM3—Signaling Pathways—SERPINE1—prostate cancer	2.81e-06	3e-05	CbGpPWpGaD
Tolterodine—CHRM1—Signaling by GPCR—KRAS—prostate cancer	2.79e-06	2.98e-05	CbGpPWpGaD
Tolterodine—CHRM2—GPCR downstream signaling—PIK3CA—prostate cancer	2.78e-06	2.98e-05	CbGpPWpGaD
Tolterodine—CHRM2—Signaling Pathways—SERPINE1—prostate cancer	2.78e-06	2.97e-05	CbGpPWpGaD
Tolterodine—CHRM3—Signaling by GPCR—KRAS—prostate cancer	2.78e-06	2.97e-05	CbGpPWpGaD
Tolterodine—CYP2C19—Metabolism—CAV1—prostate cancer	2.75e-06	2.95e-05	CbGpPWpGaD
Tolterodine—CHRM2—Signaling by GPCR—KRAS—prostate cancer	2.75e-06	2.94e-05	CbGpPWpGaD
Tolterodine—CHRM5—Signaling Pathways—VEGFA—prostate cancer	2.75e-06	2.94e-05	CbGpPWpGaD
Tolterodine—CYP2D6—Metabolism—MTHFR—prostate cancer	2.75e-06	2.94e-05	CbGpPWpGaD
Tolterodine—CYP3A4—Metabolism—SLC5A5—prostate cancer	2.74e-06	2.94e-05	CbGpPWpGaD
Tolterodine—CHRM1—Signaling Pathways—FGF2—prostate cancer	2.72e-06	2.92e-05	CbGpPWpGaD
Tolterodine—CYP2C9—Metabolism—MTHFR—prostate cancer	2.72e-06	2.91e-05	CbGpPWpGaD
Tolterodine—CHRM5—Signaling Pathways—STAT3—prostate cancer	2.72e-06	2.91e-05	CbGpPWpGaD
Tolterodine—CHRM3—Signaling Pathways—FGF2—prostate cancer	2.72e-06	2.91e-05	CbGpPWpGaD
Tolterodine—CYP2D6—Metabolism—PPARA—prostate cancer	2.69e-06	2.88e-05	CbGpPWpGaD
Tolterodine—CHRM2—Signaling Pathways—FGF2—prostate cancer	2.69e-06	2.88e-05	CbGpPWpGaD
Tolterodine—CHRM1—Signaling Pathways—NOS3—prostate cancer	2.69e-06	2.88e-05	CbGpPWpGaD
Tolterodine—CYP3A4—Metabolism—CYP2E1—prostate cancer	2.68e-06	2.87e-05	CbGpPWpGaD
Tolterodine—CHRM3—Signaling Pathways—NOS3—prostate cancer	2.68e-06	2.87e-05	CbGpPWpGaD
Tolterodine—CYP2C9—Metabolism—PPARA—prostate cancer	2.67e-06	2.86e-05	CbGpPWpGaD
Tolterodine—CHRM2—Signaling Pathways—NOS3—prostate cancer	2.65e-06	2.84e-05	CbGpPWpGaD
Tolterodine—CYP3A4—Metabolism—NQO1—prostate cancer	2.65e-06	2.84e-05	CbGpPWpGaD
Tolterodine—CHRM4—Signaling Pathways—MYC—prostate cancer	2.64e-06	2.83e-05	CbGpPWpGaD
Tolterodine—CHRM4—Signaling Pathways—TGFB1—prostate cancer	2.63e-06	2.82e-05	CbGpPWpGaD
Tolterodine—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CA—prostate cancer	2.63e-06	2.82e-05	CbGpPWpGaD
Tolterodine—CYP3A4—Metabolism—TH—prostate cancer	2.61e-06	2.8e-05	CbGpPWpGaD
Tolterodine—CHRM1—Signaling Pathways—JAK2—prostate cancer	2.61e-06	2.8e-05	CbGpPWpGaD
Tolterodine—CHRM3—Signaling Pathways—JAK2—prostate cancer	2.6e-06	2.79e-05	CbGpPWpGaD
Tolterodine—CHRM4—Signaling Pathways—EGFR—prostate cancer	2.58e-06	2.77e-05	CbGpPWpGaD
Tolterodine—CHRM2—Signaling Pathways—JAK2—prostate cancer	2.58e-06	2.76e-05	CbGpPWpGaD
Tolterodine—CHRM1—Signaling by GPCR—PIK3CA—prostate cancer	2.56e-06	2.74e-05	CbGpPWpGaD
Tolterodine—CHRM3—Metabolism—PTEN—prostate cancer	2.55e-06	2.73e-05	CbGpPWpGaD
Tolterodine—CHRM3—Signaling by GPCR—PIK3CA—prostate cancer	2.55e-06	2.73e-05	CbGpPWpGaD
Tolterodine—CHRM1—Signaling Pathways—MDM2—prostate cancer	2.55e-06	2.73e-05	CbGpPWpGaD
Tolterodine—CYP3A4—Metabolism—CYP1B1—prostate cancer	2.54e-06	2.72e-05	CbGpPWpGaD
Tolterodine—CHRM3—Signaling Pathways—MDM2—prostate cancer	2.54e-06	2.72e-05	CbGpPWpGaD
Tolterodine—CYP2D6—Metabolism—CAV1—prostate cancer	2.53e-06	2.71e-05	CbGpPWpGaD
Tolterodine—CHRM5—Signaling Pathways—MYC—prostate cancer	2.53e-06	2.71e-05	CbGpPWpGaD
Tolterodine—CHRM2—Signaling by GPCR—PIK3CA—prostate cancer	2.53e-06	2.7e-05	CbGpPWpGaD
Tolterodine—CHRM5—Signaling Pathways—TGFB1—prostate cancer	2.52e-06	2.7e-05	CbGpPWpGaD
Tolterodine—CHRM2—Signaling Pathways—MDM2—prostate cancer	2.52e-06	2.69e-05	CbGpPWpGaD
Tolterodine—CHRM1—Signaling Pathways—ERBB2—prostate cancer	2.51e-06	2.69e-05	CbGpPWpGaD
Tolterodine—CYP2C9—Metabolism—CAV1—prostate cancer	2.51e-06	2.69e-05	CbGpPWpGaD
Tolterodine—CYP2C19—Metabolism—PIK3CG—prostate cancer	2.51e-06	2.68e-05	CbGpPWpGaD
Tolterodine—CHRM3—Signaling Pathways—ERBB2—prostate cancer	2.51e-06	2.68e-05	CbGpPWpGaD
Tolterodine—CHRM2—Signaling Pathways—ERBB2—prostate cancer	2.48e-06	2.66e-05	CbGpPWpGaD
Tolterodine—CHRM1—Signaling Pathways—PIK3CB—prostate cancer	2.48e-06	2.65e-05	CbGpPWpGaD
Tolterodine—CHRM5—Signaling Pathways—EGFR—prostate cancer	2.47e-06	2.65e-05	CbGpPWpGaD
Tolterodine—CHRM3—Signaling Pathways—PIK3CB—prostate cancer	2.47e-06	2.65e-05	CbGpPWpGaD
Tolterodine—CYP3A4—Metabolism—GGT1—prostate cancer	2.46e-06	2.63e-05	CbGpPWpGaD
Tolterodine—CHRM2—Signaling Pathways—PIK3CB—prostate cancer	2.45e-06	2.62e-05	CbGpPWpGaD
Tolterodine—CHRM4—Signaling Pathways—KRAS—prostate cancer	2.44e-06	2.61e-05	CbGpPWpGaD
Tolterodine—CHRM3—Metabolism—EP300—prostate cancer	2.44e-06	2.61e-05	CbGpPWpGaD
Tolterodine—CYP3A4—Metabolism—NCOA1—prostate cancer	2.42e-06	2.59e-05	CbGpPWpGaD
Tolterodine—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CA—prostate cancer	2.4e-06	2.57e-05	CbGpPWpGaD
Tolterodine—CYP3A4—Metabolism—CYP19A1—prostate cancer	2.39e-06	2.56e-05	CbGpPWpGaD
Tolterodine—CHRM1—Signaling Pathways—CXCL8—prostate cancer	2.38e-06	2.55e-05	CbGpPWpGaD
Tolterodine—CHRM3—Signaling Pathways—CXCL8—prostate cancer	2.38e-06	2.54e-05	CbGpPWpGaD
Tolterodine—CYP2C19—Metabolism—INS—prostate cancer	2.37e-06	2.54e-05	CbGpPWpGaD
Tolterodine—CHRM2—Signaling Pathways—CXCL8—prostate cancer	2.35e-06	2.52e-05	CbGpPWpGaD
Tolterodine—CHRM5—Signaling Pathways—KRAS—prostate cancer	2.34e-06	2.5e-05	CbGpPWpGaD
Tolterodine—CHRM1—Signaling Pathways—CDKN1B—prostate cancer	2.33e-06	2.49e-05	CbGpPWpGaD
Tolterodine—CYP2C19—Metabolism—CREBBP—prostate cancer	2.33e-06	2.49e-05	CbGpPWpGaD
Tolterodine—CHRM3—Signaling Pathways—CDKN1B—prostate cancer	2.32e-06	2.48e-05	CbGpPWpGaD
Tolterodine—CYP2D6—Metabolism—PIK3CG—prostate cancer	2.31e-06	2.47e-05	CbGpPWpGaD
Tolterodine—CYP3A4—Metabolism—RXRA—prostate cancer	2.31e-06	2.47e-05	CbGpPWpGaD
Tolterodine—CHRM1—GPCR downstream signaling—AKT1—prostate cancer	2.3e-06	2.46e-05	CbGpPWpGaD
Tolterodine—CHRM2—Signaling Pathways—CDKN1B—prostate cancer	2.3e-06	2.46e-05	CbGpPWpGaD
Tolterodine—CHRM3—GPCR downstream signaling—AKT1—prostate cancer	2.29e-06	2.46e-05	CbGpPWpGaD
Tolterodine—CYP2C9—Metabolism—PIK3CG—prostate cancer	2.29e-06	2.45e-05	CbGpPWpGaD
Tolterodine—CHRM1—Signaling Pathways—CASP3—prostate cancer	2.28e-06	2.44e-05	CbGpPWpGaD
Tolterodine—CHRM1—Signaling Pathways—IL2—prostate cancer	2.28e-06	2.44e-05	CbGpPWpGaD
Tolterodine—CHRM3—Signaling Pathways—CASP3—prostate cancer	2.27e-06	2.43e-05	CbGpPWpGaD
Tolterodine—CHRM2—GPCR downstream signaling—AKT1—prostate cancer	2.27e-06	2.43e-05	CbGpPWpGaD
Tolterodine—CHRM3—Signaling Pathways—IL2—prostate cancer	2.27e-06	2.43e-05	CbGpPWpGaD
Tolterodine—CHRM1—Signaling by GPCR—IL6—prostate cancer	2.27e-06	2.43e-05	CbGpPWpGaD
Tolterodine—CHRM3—Signaling by GPCR—IL6—prostate cancer	2.26e-06	2.42e-05	CbGpPWpGaD
Tolterodine—CHRM2—Signaling Pathways—CASP3—prostate cancer	2.25e-06	2.41e-05	CbGpPWpGaD
Tolterodine—CHRM2—Signaling Pathways—IL2—prostate cancer	2.25e-06	2.41e-05	CbGpPWpGaD
Tolterodine—CHRM4—Signaling Pathways—PIK3CA—prostate cancer	2.24e-06	2.4e-05	CbGpPWpGaD
Tolterodine—CHRM2—Signaling by GPCR—IL6—prostate cancer	2.24e-06	2.39e-05	CbGpPWpGaD
Tolterodine—CYP3A4—Metabolism—COMT—prostate cancer	2.22e-06	2.38e-05	CbGpPWpGaD
Tolterodine—CHRM1—Signaling Pathways—CCND1—prostate cancer	2.22e-06	2.38e-05	CbGpPWpGaD
Tolterodine—CHRM3—Signaling Pathways—CCND1—prostate cancer	2.21e-06	2.37e-05	CbGpPWpGaD
Tolterodine—CYP3A4—Metabolism—GSTP1—prostate cancer	2.21e-06	2.37e-05	CbGpPWpGaD
Tolterodine—CYP2C19—Metabolism—PIK3CD—prostate cancer	2.2e-06	2.36e-05	CbGpPWpGaD
Tolterodine—CHRM1—Signaling Pathways—CTNNB1—prostate cancer	2.2e-06	2.35e-05	CbGpPWpGaD
Tolterodine—CHRM2—Signaling Pathways—CCND1—prostate cancer	2.19e-06	2.35e-05	CbGpPWpGaD
Tolterodine—CHRM3—Signaling Pathways—CTNNB1—prostate cancer	2.19e-06	2.35e-05	CbGpPWpGaD
Tolterodine—CYP2D6—Metabolism—INS—prostate cancer	2.18e-06	2.34e-05	CbGpPWpGaD
Tolterodine—CYP3A4—Metabolism—ITPR1—prostate cancer	2.18e-06	2.33e-05	CbGpPWpGaD
Tolterodine—CHRM2—Signaling Pathways—CTNNB1—prostate cancer	2.17e-06	2.32e-05	CbGpPWpGaD
Tolterodine—CHRM4—Signaling Pathways—TP53—prostate cancer	2.17e-06	2.32e-05	CbGpPWpGaD
Tolterodine—CYP2C9—Metabolism—INS—prostate cancer	2.16e-06	2.32e-05	CbGpPWpGaD
Tolterodine—CHRM1—Signaling Pathways—MMP9—prostate cancer	2.16e-06	2.31e-05	CbGpPWpGaD
Tolterodine—CHRM3—Signaling Pathways—MMP9—prostate cancer	2.15e-06	2.3e-05	CbGpPWpGaD
Tolterodine—CHRM1—Signaling Pathways—CDKN1A—prostate cancer	2.15e-06	2.3e-05	CbGpPWpGaD
Tolterodine—CHRM5—Signaling Pathways—PIK3CA—prostate cancer	2.15e-06	2.3e-05	CbGpPWpGaD
Tolterodine—CHRM1—Signaling Pathways—PTEN—prostate cancer	2.14e-06	2.29e-05	CbGpPWpGaD
Tolterodine—CHRM3—Signaling Pathways—CDKN1A—prostate cancer	2.14e-06	2.29e-05	CbGpPWpGaD
Tolterodine—CYP2D6—Metabolism—CREBBP—prostate cancer	2.14e-06	2.29e-05	CbGpPWpGaD
Tolterodine—CHRM3—Signaling Pathways—PTEN—prostate cancer	2.14e-06	2.29e-05	CbGpPWpGaD
Tolterodine—CHRM2—Signaling Pathways—MMP9—prostate cancer	2.13e-06	2.28e-05	CbGpPWpGaD
Tolterodine—CYP2C9—Metabolism—CREBBP—prostate cancer	2.12e-06	2.27e-05	CbGpPWpGaD
Tolterodine—CHRM2—Signaling Pathways—CDKN1A—prostate cancer	2.12e-06	2.27e-05	CbGpPWpGaD
Tolterodine—CHRM2—Signaling Pathways—PTEN—prostate cancer	2.12e-06	2.26e-05	CbGpPWpGaD
Tolterodine—CHRM1—Signaling by GPCR—AKT1—prostate cancer	2.09e-06	2.24e-05	CbGpPWpGaD
Tolterodine—CHRM3—Signaling by GPCR—AKT1—prostate cancer	2.08e-06	2.23e-05	CbGpPWpGaD
Tolterodine—CYP2C19—Metabolism—NOS3—prostate cancer	2.08e-06	2.23e-05	CbGpPWpGaD
Tolterodine—CHRM5—Signaling Pathways—TP53—prostate cancer	2.08e-06	2.22e-05	CbGpPWpGaD
Tolterodine—CHRM2—Signaling by GPCR—AKT1—prostate cancer	2.06e-06	2.21e-05	CbGpPWpGaD
Tolterodine—CYP3A4—Metabolism—TYMS—prostate cancer	2.05e-06	2.2e-05	CbGpPWpGaD
Tolterodine—CHRM1—Signaling Pathways—EP300—prostate cancer	2.04e-06	2.19e-05	CbGpPWpGaD
Tolterodine—CHRM3—Signaling Pathways—EP300—prostate cancer	2.04e-06	2.18e-05	CbGpPWpGaD
Tolterodine—CYP3A4—Metabolism—GSTM1—prostate cancer	2.03e-06	2.17e-05	CbGpPWpGaD
Tolterodine—CYP2D6—Metabolism—PIK3CD—prostate cancer	2.03e-06	2.17e-05	CbGpPWpGaD
Tolterodine—CHRM2—Signaling Pathways—EP300—prostate cancer	2.02e-06	2.16e-05	CbGpPWpGaD
Tolterodine—CYP2C9—Metabolism—PIK3CD—prostate cancer	2.01e-06	2.15e-05	CbGpPWpGaD
Tolterodine—CYP3A4—Metabolism—LPL—prostate cancer	1.99e-06	2.13e-05	CbGpPWpGaD
Tolterodine—CHRM1—Signaling Pathways—SRC—prostate cancer	1.99e-06	2.13e-05	CbGpPWpGaD
Tolterodine—CHRM4—Signaling Pathways—IL6—prostate cancer	1.99e-06	2.13e-05	CbGpPWpGaD
Tolterodine—CHRM3—Signaling Pathways—SRC—prostate cancer	1.98e-06	2.12e-05	CbGpPWpGaD
Tolterodine—CHRM2—Signaling Pathways—SRC—prostate cancer	1.96e-06	2.1e-05	CbGpPWpGaD
Tolterodine—CHRM1—Signaling Pathways—VEGFA—prostate cancer	1.94e-06	2.07e-05	CbGpPWpGaD
Tolterodine—CHRM3—Signaling Pathways—VEGFA—prostate cancer	1.93e-06	2.07e-05	CbGpPWpGaD
Tolterodine—CYP3A4—Metabolism—CYP1A1—prostate cancer	1.93e-06	2.06e-05	CbGpPWpGaD
Tolterodine—CYP2C19—Metabolism—PIK3CB—prostate cancer	1.92e-06	2.06e-05	CbGpPWpGaD
Tolterodine—CHRM1—Signaling Pathways—STAT3—prostate cancer	1.92e-06	2.05e-05	CbGpPWpGaD
Tolterodine—CYP2D6—Metabolism—NOS3—prostate cancer	1.92e-06	2.05e-05	CbGpPWpGaD
Tolterodine—CHRM2—Signaling Pathways—VEGFA—prostate cancer	1.91e-06	2.05e-05	CbGpPWpGaD
Tolterodine—CHRM3—Signaling Pathways—STAT3—prostate cancer	1.91e-06	2.05e-05	CbGpPWpGaD
Tolterodine—CYP3A4—Metabolism—ERCC2—prostate cancer	1.91e-06	2.04e-05	CbGpPWpGaD
Tolterodine—CYP2C19—Metabolism—PTGS2—prostate cancer	1.9e-06	2.04e-05	CbGpPWpGaD
Tolterodine—CHRM5—Signaling Pathways—IL6—prostate cancer	1.9e-06	2.04e-05	CbGpPWpGaD
Tolterodine—CYP2C9—Metabolism—NOS3—prostate cancer	1.9e-06	2.03e-05	CbGpPWpGaD
Tolterodine—CHRM2—Signaling Pathways—STAT3—prostate cancer	1.89e-06	2.03e-05	CbGpPWpGaD
Tolterodine—CHRM4—Signaling Pathways—AKT1—prostate cancer	1.83e-06	1.96e-05	CbGpPWpGaD
Tolterodine—CHRM3—Metabolism—PIK3CA—prostate cancer	1.8e-06	1.93e-05	CbGpPWpGaD
Tolterodine—CYP3A4—Metabolism—MTHFR—prostate cancer	1.8e-06	1.92e-05	CbGpPWpGaD
Tolterodine—CHRM1—Signaling Pathways—MYC—prostate cancer	1.78e-06	1.91e-05	CbGpPWpGaD
Tolterodine—CHRM1—Signaling Pathways—TGFB1—prostate cancer	1.78e-06	1.9e-05	CbGpPWpGaD
Tolterodine—CHRM3—Signaling Pathways—MYC—prostate cancer	1.78e-06	1.9e-05	CbGpPWpGaD
Tolterodine—CHRM3—Signaling Pathways—TGFB1—prostate cancer	1.77e-06	1.9e-05	CbGpPWpGaD
Tolterodine—CYP2D6—Metabolism—PIK3CB—prostate cancer	1.77e-06	1.89e-05	CbGpPWpGaD
Tolterodine—CYP3A4—Metabolism—PPARA—prostate cancer	1.76e-06	1.89e-05	CbGpPWpGaD
Tolterodine—CHRM2—Signaling Pathways—MYC—prostate cancer	1.76e-06	1.88e-05	CbGpPWpGaD
Tolterodine—CHRM5—Signaling Pathways—AKT1—prostate cancer	1.75e-06	1.88e-05	CbGpPWpGaD
Tolterodine—CHRM2—Signaling Pathways—TGFB1—prostate cancer	1.75e-06	1.88e-05	CbGpPWpGaD
Tolterodine—CYP2C9—Metabolism—PIK3CB—prostate cancer	1.75e-06	1.88e-05	CbGpPWpGaD
Tolterodine—CYP2D6—Metabolism—PTGS2—prostate cancer	1.75e-06	1.87e-05	CbGpPWpGaD
Tolterodine—CHRM1—Signaling Pathways—EGFR—prostate cancer	1.74e-06	1.86e-05	CbGpPWpGaD
Tolterodine—CYP2C9—Metabolism—PTGS2—prostate cancer	1.74e-06	1.86e-05	CbGpPWpGaD
Tolterodine—CHRM3—Signaling Pathways—EGFR—prostate cancer	1.74e-06	1.86e-05	CbGpPWpGaD
Tolterodine—CHRM2—Signaling Pathways—EGFR—prostate cancer	1.72e-06	1.84e-05	CbGpPWpGaD
Tolterodine—CYP2C19—Metabolism—PTEN—prostate cancer	1.66e-06	1.78e-05	CbGpPWpGaD
Tolterodine—CYP3A4—Metabolism—CAV1—prostate cancer	1.66e-06	1.77e-05	CbGpPWpGaD
Tolterodine—CHRM1—Signaling Pathways—KRAS—prostate cancer	1.65e-06	1.76e-05	CbGpPWpGaD
Tolterodine—CHRM3—Signaling Pathways—KRAS—prostate cancer	1.64e-06	1.76e-05	CbGpPWpGaD
Tolterodine—CHRM2—Signaling Pathways—KRAS—prostate cancer	1.62e-06	1.74e-05	CbGpPWpGaD
Tolterodine—CYP2C19—Metabolism—EP300—prostate cancer	1.58e-06	1.7e-05	CbGpPWpGaD
Tolterodine—CYP2D6—Metabolism—PTEN—prostate cancer	1.53e-06	1.64e-05	CbGpPWpGaD
Tolterodine—CYP2C9—Metabolism—PTEN—prostate cancer	1.51e-06	1.62e-05	CbGpPWpGaD
Tolterodine—CHRM1—Signaling Pathways—PIK3CA—prostate cancer	1.51e-06	1.62e-05	CbGpPWpGaD
Tolterodine—CYP3A4—Metabolism—PIK3CG—prostate cancer	1.51e-06	1.61e-05	CbGpPWpGaD
Tolterodine—CHRM3—Signaling Pathways—PIK3CA—prostate cancer	1.51e-06	1.61e-05	CbGpPWpGaD
Tolterodine—CHRM2—Signaling Pathways—PIK3CA—prostate cancer	1.49e-06	1.6e-05	CbGpPWpGaD
Tolterodine—CHRM3—Metabolism—AKT1—prostate cancer	1.47e-06	1.58e-05	CbGpPWpGaD
Tolterodine—CHRM1—Signaling Pathways—TP53—prostate cancer	1.46e-06	1.57e-05	CbGpPWpGaD
Tolterodine—CHRM3—Signaling Pathways—TP53—prostate cancer	1.46e-06	1.56e-05	CbGpPWpGaD
Tolterodine—CYP2D6—Metabolism—EP300—prostate cancer	1.46e-06	1.56e-05	CbGpPWpGaD
Tolterodine—CYP2C9—Metabolism—EP300—prostate cancer	1.44e-06	1.55e-05	CbGpPWpGaD
Tolterodine—CHRM2—Signaling Pathways—TP53—prostate cancer	1.44e-06	1.55e-05	CbGpPWpGaD
Tolterodine—CYP3A4—Metabolism—INS—prostate cancer	1.43e-06	1.53e-05	CbGpPWpGaD
Tolterodine—CYP3A4—Metabolism—CREBBP—prostate cancer	1.4e-06	1.5e-05	CbGpPWpGaD
Tolterodine—CHRM1—Signaling Pathways—IL6—prostate cancer	1.34e-06	1.43e-05	CbGpPWpGaD
Tolterodine—CHRM3—Signaling Pathways—IL6—prostate cancer	1.33e-06	1.43e-05	CbGpPWpGaD
Tolterodine—CYP3A4—Metabolism—PIK3CD—prostate cancer	1.33e-06	1.42e-05	CbGpPWpGaD
Tolterodine—CHRM2—Signaling Pathways—IL6—prostate cancer	1.32e-06	1.41e-05	CbGpPWpGaD
Tolterodine—CYP3A4—Metabolism—NOS3—prostate cancer	1.25e-06	1.34e-05	CbGpPWpGaD
Tolterodine—CHRM1—Signaling Pathways—AKT1—prostate cancer	1.24e-06	1.32e-05	CbGpPWpGaD
Tolterodine—CHRM3—Signaling Pathways—AKT1—prostate cancer	1.23e-06	1.32e-05	CbGpPWpGaD
Tolterodine—CHRM2—Signaling Pathways—AKT1—prostate cancer	1.22e-06	1.31e-05	CbGpPWpGaD
Tolterodine—CYP2C19—Metabolism—PIK3CA—prostate cancer	1.17e-06	1.25e-05	CbGpPWpGaD
Tolterodine—CYP3A4—Metabolism—PIK3CB—prostate cancer	1.16e-06	1.24e-05	CbGpPWpGaD
Tolterodine—CYP3A4—Metabolism—PTGS2—prostate cancer	1.15e-06	1.23e-05	CbGpPWpGaD
Tolterodine—CYP2D6—Metabolism—PIK3CA—prostate cancer	1.08e-06	1.15e-05	CbGpPWpGaD
Tolterodine—CYP2C9—Metabolism—PIK3CA—prostate cancer	1.07e-06	1.14e-05	CbGpPWpGaD
Tolterodine—CYP3A4—Metabolism—PTEN—prostate cancer	9.99e-07	1.07e-05	CbGpPWpGaD
Tolterodine—CYP2C19—Metabolism—AKT1—prostate cancer	9.57e-07	1.02e-05	CbGpPWpGaD
Tolterodine—CYP3A4—Metabolism—EP300—prostate cancer	9.52e-07	1.02e-05	CbGpPWpGaD
Tolterodine—CYP2D6—Metabolism—AKT1—prostate cancer	8.8e-07	9.42e-06	CbGpPWpGaD
Tolterodine—CYP2C9—Metabolism—AKT1—prostate cancer	8.73e-07	9.34e-06	CbGpPWpGaD
Tolterodine—CYP3A4—Metabolism—PIK3CA—prostate cancer	7.05e-07	7.54e-06	CbGpPWpGaD
Tolterodine—CYP3A4—Metabolism—AKT1—prostate cancer	5.76e-07	6.16e-06	CbGpPWpGaD
